Zymeworks (ZYME) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zymeworks has achieved a significant milestone with the FDA’s accelerated approval of Ziihera, a dual HER2-targeted bispecific antibody for HER2-positive biliary tract cancer (BTC). This approval not only validates Zymeworks’ innovative Azymetric™ technology but also secures a $25 million milestone payment from Jazz Pharmaceuticals, with the potential for further financial gains through regulatory milestones.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
